Clinical Trial Update: Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib

View source ↗

Summary

The study investigates whether EGFR gene mutations in non-small cell lung cancer predict response to the EGFR inhibitor erlotinib. The trial status is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Aarhus University Hospital | Conditions: Non-Small Cell Lung Cancer | Status: UNKNOWN